Expiration date: 12/2022
Description of the active substance (INN): Memantine
Antiparkinsonian agent. Possesses nootropic, cerebrovasculature, antihypoxic and psychoactive effect. Adamantane derivative, the chemical structure and pharmacological properties similar to amantadine. Blocks glutamate NMDA receptors (substantia nigra), thus reducing the excessive stimulatory effect of cortical glutamate neurons in neostriatum developing on the background of inadequate allocation of dopamine. Reducing the flow of ionized Ca2+ in neurons, reduces the possibility of their destruction. A greater impact on stiffness (rigidity and bradykinesia). Improves weakened memory, concentration, reduces fatigue and symptoms of depression, reduces spasticity caused by diseases and injuries of the brain.
Parkinson's disease, syndrome of parkinsonism. Spasticity of the skeletal muscles (TBI, stroke, multiple sclerosis). Disorders of brain function mild and moderate degrees of severity: weakening memory, decline of interest in surroundings, decreased ability to concentrate.
Hypersensitivity, renal failure, pregnancy, lactation.C caution. Thyrotoxicosis, epilepsy.
Dizziness, irritability, excessive fatigue, anxiety, increased intracranial pressure, nausea.
Method of application and dose:
The initial dose for adults - 5 mg/day. The dose may be increased to 5 mg/week. The average maintenance dose - 10-20 mg/day (30-60 mg). Children - 500 mg/kg/day. Last appointment it is advisable to recommend in the second half of the day. In the treatment of cerebral spasticity you can enter. If impaired renal function the dose should be reduced.
Enhances the effect of barbiturates, antipsychotics and anticholinergic drugs.
Description of the drug Memantine Akatinol is not intended to assign treatment without a doctor.